Systemic inflammatory biomarkers in Schizophrenia are changed by ECT administration and related to the treatment efficacy
- PMID: 38233774
- PMCID: PMC10792810
- DOI: 10.1186/s12888-023-05469-2
Systemic inflammatory biomarkers in Schizophrenia are changed by ECT administration and related to the treatment efficacy
Abstract
Immune inflammation has long been implicated in the pathogenesis of schizophrenia. Despite as a rapid and effective physical therapy, the role of immune inflammation in electroconvulsive therapy (ECT) for schizophrenia remains elusive. The neutrophils to lymphocytes (NLR), platelets to monocytes (PLR) and monocytes to lymphocytes (MLR) are inexpensive and accessible biomarkers of systemic inflammation. In this study, 70 schizophrenia patients and 70 age- and sex-matched healthy controls were recruited. The systemic inflammatory biomarkers were measured before and after ECT. Our results indicated schizophrenia had significantly higher peripheral NLR, PLR and MLR compared to health controls at baseline, while lymphocytes did not differ. After 6 ECT, the psychiatric symptoms were significantly improved, as demonstrated by the Positive and Negative Syndrome Scale (PANSS). However, there was a decline in cognitive function scores, as indicated by the Mini-Mental State Examination (MMSE). Notably, the neutrophils and NLR were significantly reduced following ECT. Although lymphocytes remained unchanged following ECT, responders had significantly higher lymphocytes compared to non-responders. Moreover, the linear regression analyses revealed that higher lymphocytes served as a predictor of larger improvement in positive symptom following ECT. Overall, our findings further highlighted the presence of systemic inflammation in schizophrenia patients, and that ECT may exert a therapeutic effect in part by attenuating systemic inflammation. Further research may therefore lead to new treatment strategies for schizophrenia targeting the immune system.
Keywords: Electroconvulsive therapy; Inflammation; Lymphocytes; NLR; Neutrophils; Schizophrenia.
© 2024. The Author(s).
Conflict of interest statement
No potential conflict of interests to declare.
Figures

Similar articles
-
The role of immune inflammation in electroconvulsive therapy for schizophrenia: Treatment mechanism, and relationship with clinical efficacy: Immune-inflammation in ECT for schizophrenia.Psychiatry Res. 2024 Feb;332:115708. doi: 10.1016/j.psychres.2023.115708. Epub 2023 Dec 31. Psychiatry Res. 2024. PMID: 38171169 Review.
-
The association between inflammation and kynurenine pathway metabolites in electroconvulsive therapy for schizophrenia: Implications for clinical efficacy.Brain Behav Immun. 2023 Oct;113:1-11. doi: 10.1016/j.bbi.2023.06.016. Epub 2023 Jun 21. Brain Behav Immun. 2023. PMID: 37353059
-
Effects of Electroconvulsive Therapy on Some Inflammatory Factors in Patients With Treatment-Resistant Schizophrenia.J ECT. 2016 Sep;32(3):174-9. doi: 10.1097/YCT.0000000000000303. J ECT. 2016. PMID: 26886746
-
Nerve growth factor serum levels in treatment-resistant schizophrenic patients following electroconvulsive therapy.Clin Ter. 2021 Jan-Feb;171(1):e67-e74. doi: 10.7417/CT.2021.2286. Clin Ter. 2021. PMID: 33346332
-
Electroconvulsive therapy for treatment-resistant schizophrenia.Cochrane Database Syst Rev. 2019 Mar 19;3(3):CD011847. doi: 10.1002/14651858.CD011847.pub2. Cochrane Database Syst Rev. 2019. PMID: 30888709 Free PMC article.
Cited by
-
The relationship between neurodevelopmental disorders (NDDs) and NLRP3 inflammasome.Inflamm Res. 2025 Jun 3;74(1):90. doi: 10.1007/s00011-025-02052-1. Inflamm Res. 2025. PMID: 40457054 Review.
-
Altered serum glutathione disulfide levels in acute relapsed schizophrenia are associated with clinical symptoms and response to electroconvulsive therapy.BMC Psychiatry. 2025 Mar 14;25(1):242. doi: 10.1186/s12888-025-06691-w. BMC Psychiatry. 2025. PMID: 40087601 Free PMC article.
-
Differences in Blood Leukocyte Subpopulations in Schizophrenia: A Systematic Review and Meta-Analysis.JAMA Psychiatry. 2025 May 1;82(5):492-504. doi: 10.1001/jamapsychiatry.2024.4941. JAMA Psychiatry. 2025. PMID: 40042836
References
-
- Weye N, Santomauro DF, Agerbo E, Christensen MK, Iburg KM, Momen NC, Mortensen PB, Pedersen CB, Whiteford HA, McGrath JJ, et al. Register-based metrics of years lived with disability associated with mental and substance use disorders: a register-based cohort study in Denmark. The Lancet Psychiatry. 2021;8(4):310–9. doi: 10.1016/S2215-0366(21)00029-8. - DOI - PubMed
-
- Park GH, Noh H, Shao Z, Ni P, Qin Y, Liu D, Beaudreault CP, Park JS, Abani CP, Park JM, et al. Activated microglia cause metabolic disruptions in developmental cortical interneurons that persist in interneurons from individuals with schizophrenia. Nat Neurosci. 2020;23(11):1352–64. doi: 10.1038/s41593-020-00724-1. - DOI - PMC - PubMed
-
- Nunez C, Stephan-Otto C, Usall J, Bioque M, Lobo A, Gonzalez-Pinto A, Pina-Camacho L, Vieta E, Castro-Fornieles J, Rodriguez-Jimenez R, et al. Neutrophil Count is Associated with reduced Gray Matter and Enlarged ventricles in First-Episode Psychosis. Schizophr Bull. 2019;45(4):846–58. doi: 10.1093/schbul/sby113. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 81971255/the National Natural Science Foundation of China
- No. BE2019610/Social Development Foundation of Jiangsu Province, China
- YKK20090/the Key Project supported by Medical Science and Technology Development Foundation, Nanjing Department of Health
- NMUB2019107/the Science and Technology Development Program of Nanjing Medical University
- 82371510/the National NaturalScience Foundation of China
LinkOut - more resources
Full Text Sources
Medical